Cairo – Gilead Sciences signed a non-exclusive licensing agreement with Eva Pharma for manufacturing and selling remdesivir, a promising treatment for coronavirus (COVID-19), in 127 countries, including Egypt.

Under the deal, Eva Pharma, along with other companies based in India and Pakistan, “will have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly,” according to a recent statement.

“The licensees also set their own prices for the generic product they produce,” the statement showed.

The initial clinical trials have shown that remdesivir may improve recovery time for people with moderate to critical symptoms.

The licence is royalty-free until the the end of the public heath emergency, or another drug or vaccine is approved for treatment or prevention of the virus.

Source: Mubasher

All Rights Reserved - Mubasher Info © 2005 - 2020 Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.